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INTRODUCTION 
Urinary stone disease is a common disease affecting mankind 
and it was described since historical times. The life time risk of 
developing stone disease was 1% to 15 % 1. It varies between races, 
geographical area of living, age2, gender, occupation etc...  
Generally there is increased prevalence of stone disease in western 
countries when compared to south Asian countries, but due to 
westernization of culture in these countries there is increased 
incidence of nephrolithiasis. 
Nephrolithiasis were polycrystalline aggregates containing 
various proportions of crystal and organic matrix components. The 
common nephrolithiasis calculus were calcium oxalate stones, 
calcium phosphate stones,uric  acid stones,calcium magnesium 
ammonium phosphate stone (triple phosphate stone or struvite  
stone) and cystine stone. 
Due to advances in the investigation modalities for the 
diagnosis of nephrolithiasis, stone disease was increasingly 
diagnosed prior to their symptomatic presentation. And also due to 
marked advancement in technology, nephrolithiasis were 
increasingly treated by non invasive methods like Extra corporial 
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Lithotripsy (ESWL) and by minimal invasive procedures like Per 
cutaneous nephrolithotomy (PCNL). These procedures treat the 
nephrolithiasis patients with less morbidity and with good results. 
Because of profound morbidity due to the disease and during 
treatment, loss of renal function with end stage renal disease in 
some neglected cases and increased cost of expenditure for 
diagnosis and treatment, there was shift of focus from treatment to 
prevention of nephrolithiasis.  
The development of nephrolithiasis was most likely a multi 
factorial process and it is not fully addressed by current theories. 
Metabolic syndrome3 is a complex of medical disorders; when 
they occur together have clinical significance like increased risk of 
developing cardiovascular disease, cerebrovascular accidents, 
diabetes mellitus (type two) and atherosclerosis. There are different 
definitions for defining metabolic syndrome and they all include the 
main components – obesity or waist circumference, hypertension, 
hyperlipidemia and hyperglycemia.  
The associations of metabolic syndrome with nephrolithiasis 
were showed by many studies4 in a defined population. The exact 
patho -physiology of this association was not clear, but shown to be 
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associated with metabolic syndrome patient’s urinary constituents 
like decrease in urinary PH, increased urinary calcium and uric acid 
excretion and decreased excretion of urinary citrate which is an 
important inhibitor of nephrolithiasis.  
We investigate this association in patient population in our 
institute with nephrolithiasis and compare with individuals without 
nephrolithiasis. 
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AIM AND OBJECTIVE 
The aim of this study was 
 To evaluate the relationship between metabolic syndrome and 
nephrolithiasis 
 To evaluates the relationship between each metabolic 
syndrome constituents with nephrolithiasis. 
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REVIEW OF LITERATURE 
Renal calculus disease can be divided in to two broad groups 
on the basis of location of calcification in kidney. Nephrolithiasis 
was the term used to describe presence of calculus in renal pelvic 
calyceal system. The presence of calculus in the renal parenchyma 
was termed as nephrocalcinosis. The word “calculus” is derived 
from Latin that means “pebble”. Nephrolithiasis   affected mankind 
more than a thousand years. A 1.5 cms size nephrolithiasis was 
noted in an Egyptian mummy in a tomp dated 4400 B.C5. Although 
nephrolithiasis found in human in the ancient time, only in the past 
200 years it was investigated and analysed on scientific basis. The 
chemical constituents of urinary calculus was first described with 
uric acid stones and was called acid of calculus or lithic acid 
(Greek word lithic means stone) .  
From ancient history the treatment of stone disease had 
progressed from portions and prayers to external application (hot 
water) 6 to destructive treatment (nephrectomy for nephrolithiasis 
and its sequel) to curative treatment (removal of stone by surgery) 
to preventive treatments.  
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For making diagnosis of nephrolithiasis it is crucial to have 
imaging instruments.  The first important event was the invention 
of X- ray by Roentgen in 1895. The first radiograph showing 
nephrolithiasis was taken by John Macintyre, a Scottish physician 
in 1896. By using plain X- ray film, nephrolithiasis were classified 
in two types: Radio opaque calculus and radiolucent calculus 
depending on the presence of calcium7. Calcium containing 
calculus like calcium oxalate, calcium phosphate, Struvite or triple 
phosphate calculi were radio opaque on plain film. They account to 
90% of the renal calculus disease. Cystine stones were moderately 
radio opaque when compared to calcium containing stone and have 
homogenous ground glass opacity. The radio opacity was due to 
high physical density, high atomic number and sulphur content8. 
Pure uric acid calculus, matrix calculus and xanthine calculus were 
radio lucent.  
The functional and anatomical studies of urinary tract were 
done after the invention of iodinated contrast material ‘uroselectan’ 
by Moses Swick et al in 19289. Intra venous Urography confirms 
the intra renal location of calculus and tells about exact location of 
calculus in relation to pelvic calyceal anatomy which was used in 
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the management of nephrolithiasis and also shows presence of 
anatomical abnormality which predispose to calculus formation.  
The use of ultrasonogram in medicine begins after Second 
World War. The first published work on medical use of 
ultrasonogram was done by Dr. Theodore Dussik10 in Austria on 
transmission of ultrasound waves during his imaging of brain. 
Another scientist named Professor Ian Donald of Scotland 
improved the technology and devised practical technology and 
ultrasound application in clinical use in 1950. Ultrasonography was 
an important imaging modality in the diagnosis and the localization 
of nephrolithiasis. Ultrasound imaging results from interaction of 
sound waves with tissues and other structures in body. The 
frequency of sound waves used in Urology was 3.5MHz to 5MHz.  
Image production in ultrasonography starts with transducer. 
Transducer used here has two functions as producer of ultrasonic 
waves and also as receiver of reflected mechanical sound. These 
received sounds were converted into electrical energy which was in 
turn converted into image by ultra sound machine. Gray scale B 
mode ultrasonography was commonly used in Urology producing 
real time two dimensional images containing shades of gray. Most 
of the renal calculi were seen as bright echogenic foci with post 
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acoustic shadow. Even radiolucent uric acid and xanthine calculus 
were visualized using this modality with the exception of Indinavir 
calculus11 in patients with AIDS. Matrix calculus was visualized as 
echogenic foci without post acoustic shadow12.  
Middleton et al 13 concluded from their study that 
Ultrasonographic ability to diagnose nephrolithiasis was influenced 
by calculus size but not calculus position or obesity of the patient. 
For better visualization of renal calculus focal zone should be kept 
at depth of the stone or slightly deeper. In this study they showed 
100% sensitivity for visualizing calculus of size 5mm or more, 96% 
sensitivity for calculus of size 2.6mm to 5mm and 85% for calculus 
of size less than 2.5mm. Again real time imaging was more 
sensitive than static images due to difficult to demonstrate post 
acoustic shadow in static images.  
Ultrasonography also used in guiding therapy for 
nephrolithiasis in extracorporeal shock wave lithotripsy and 
laparoscopic nephrolithotomy. Ultrasonography has the advantage 
of non invasive modality and can be used in patients with increased 
renal parameters, allergy to contrast material and in patients where 
radiation cannot be used as in pregnancy and also in the follow up. 
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False positive diagnosis of nephrolithiasis were made in renal 
arterial calcification and in patients with intra renal gas. 
After the invention of computer tomography by Sir Godfrey 
Newbold Hounsfield 14 in 1940, it became the most commonly used 
imaging tool for diagnosis of nephrolithiasis. He received noble 
prize for physics in 1976. Computer Tomography (CT) have better 
contrast resolution so all stones except pure matrix calculus and 
Indinavir calculus, appear dense when compared to surrounding 
soft tissues. Non contrast spiral CT has high sensitivity15,16 in 
detecting nephrolithiasis but low specificity because it do not 
distinguish nephrolithiasis from Randall’s plaque and sub mucosal 
stone. The density of nephrolithiasis can be measured in CT 
images, which predicts the hardness of the stone. The disadvantages 
of CT were increased radiation exposure, patients may have allergic 
reactions and contrast induced nephropathy when contrast was 
used. 
PATHOPHYSIOLOGY OF CALCULUS FORMATION 
Nephrolithiasis contains large amount of crystalline material 
(97%-98%) and organic matrix providing the framework for 
deposition of crystals17. The calculus formation process was a 
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complex and continuous process that occur as urine filtered from 
the glomerulus moves along the nephrons.  Once calculus was 
formed they may come out along with urine formed or captured 
inside the pelvic calyceal system of kidney with promotion of 
growth. 
Calculus formation starts when  
1) There is excess excretion of calculus forming salts and 
precipitation to form nuclei or crystal. 
2) There is decrease in substance that inhibits crystal deposition. 
3) There is availability of specific macromolecules needed for 
calculus formation.  
A solution containing molecules or ions of difficult solubility 
salt was called as Concentration Product (CP). It can be 
mathematically expressed as product of concentration of pure 
chemical components of that salt. For example CP of sodium 
chloride was expressed as  
[NaCl]  = [Na+][Cl-] 
A solution has been considered as saturated when further 
adding of salt will not cause mixing of solvent in the solution. The 
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CP at this point of saturation of solution was called thermodynamic 
Solubility Product (Ksp) , when further crystals were added at this 
point there will be precipitation unless the solution temperature or 
pH  were altered. 
In Glomerular filtrate even when calculus forming salt 
constituents (calcium oxalate) exceed Ksp, crystallization do not 
occur due to presence of inhibitors of crystal formation. The 
calculus formation inhibitors present in urine were citrate, 
glycosaminoglycan like heparin sulfate, magnesium, RNA, acid 
mucopolysaccharides and urinary glycoproteins like Tamm Horsfall 
glycoprotein and nephrocalcin. Citrate was an important inhibitor 
of nephrolithisis and it acts by 
1) It reduces the calcium salts saturation in urine by combining 
with calcium. 
2) Directly prevents calcium oxalate nucleation. 
3) It inhibits precipitation and growth of Calcium Oxalate 
crystals. 
4) It enhances Tamm Horsfall glycoprotein’s inhibitory effect 
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  These inhibitors allow high concentration of Calcium 
Oxalate crystals in the state of solution. This point of saturation 
was called as metastable state. On further increase in salt 
concentration a stage was reached at which crystal forms in urine.  
The CP at this state was termed as formation Product (Kf). 
Solubility Product (Ksp) and Formation Product (Kf) 
differentiates urine in three forms. 
1) Under saturated 
2) Metastable 
3) Unstable  
In under saturated state of urine (below solubility product) 
crystal does not form under any period and dissolution of formed 
crystal was possible. In unstable state of urine (above formation 
product) crystal will form. Here the supersaturated solution 
deposits excess crystal material in solution as solid particle and this 
process was called nucleation18.  In metastable state of urine 
(between Formation Product and Solubility Product) spon-taneous 
nucleation does not form even when the urine was supersaturated.   
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In this state calculus growth will be possible over an already 
formed crystal; per se calculus formation will not be possible in the 
time taken by the urine formed normally in the glomerulus to reach 
urinary bladder in the pelvis. Here calculus formation occur in 
some situations like 
1) In some areas of nephrons where the local area concentration 
product (CP) exceeds the formation product (Kf) for 
prolonged period to favor nucleation to form. 
2) When there is local obstruction in the renal pelvis, calyx or 
ureter, the transit time of urine in kidney will be prolonged 
causing crystal formation. 
3) Microscopic impurities in urine may facilitate nucleation by 
absorption of crystal components on their surface. 
Heterogeneous Nucleation thus formed normally requires 
very less energy than the other form of nucleation.  
Nephrolithiasis contains mainly mixed calculus, often a 
combination of calcium phosphate and calcium oxalate. Normally 
calcium oxalate crystalli-zation starts by heterogeneous nucleation. 
Calcium phosphate may serve as nidus. Hydroxyapatite was stable 
in alkaline urine and the crystal of hydroxyapatite may induce 
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growth of calcium oxalate monohydrate crystal in a metastable state 
of urine19. Dicalcium phosphate dihydrate was stable form in acidic 
urine and can induce hetero-geneous nucleation of calcium oxalate 
calculus 20,21. From these findings it can be proposed that 
nephrolithiasis was formed from calcium salts in a metastable urine 
by heterogeneous nucleation.  
The newly formed crystals can be excreted in urine as 
crystalluria or enlarge to become clinically significant calculus in 
the kidney.  Calculi were much larger in size that cannot be 
explained only by crystal nucleation theory. So there must be other 
theory to explain the mechanism of growth of crystal and their 
containment in kidney to over come their excretion in urine. 
Crystals will bind with each other by the process aggregation or 
agglomeration. Here many particles were held - together by inter 
molecular forces which resist shear forces. Crystalline aggregations 
were seen to form in the center of urinary calculus particularly in 
wedellite, whewellite, uric acid and brushite calculus22. 
Nephrolithiasis were usually multi component, have distinct 
concentric rings when sectioned. Consecutive layers have different 
components but each layer have homogenous crystalline 
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composition. Epitaxy was a process of oriented growth of a single 
crystalline lattice over another crystalline lattice23.  
Calculus analysis shows it contain crystalline and non 
crystalline component. This non crystalline component was termed 
as matrix. In nephrolithiasis the matrix commonly account to 2-3 
%24. In matrix stone the percentage of matrix may be up to 65 
%25,26. By chemical analysis matrix stone contains 65% 
hexosamine, 10% water, substance A, nephrocalcin28, Tamm-
Horsfall glycoprotein29, albumin and glycosaminoglycan30. After 
formation if nucleated crystals were flushed by urine, calculus will 
not be formed. Crystal retention was an important factor and occurs 
if it adheres to the urothelium or if it grows to a large size to be 
trapped in the tubule. The first evidence of crystal retention has 
been showed by Randall in1940 as plaques of sub epithelial 
deposits of calcium crystals in renal papillae31 .  These plaques were 
called Randall’s plaques which act as a nidus for urinary calculus 
formation.  
Stoller et al.32 showed papillary calcifications in 57% of 
cadaveric kidneys when imaged by using high resolution 
 16 
radiography. They also observed correlation between papillary 
calcifications and patient’s hypertensive history.   
  Normal urothelium in the urinary tract have some safety 
mechanism against nucleation of crystal and attachment of calcium 
oxalate crystals33. When there is chemical injury to the urothelium 
in kidney, there will be failure of this protective property 
predisposing to adhesion of calcium oxalate crystals. Normal 
urothelium has a layer of glycosaminoglycan34 which prevents 
adherence of bacteria and prevents adhesion of crystals.    
Nephrolithiasis contains mostly calcium (75%).  So it was 
classified in to calcium containing calculus and non calcium 
containing calculus35. 
Calcium-Containing calculus 
 Calcium oxalate – 60% 
 Hydroxyapatite- 20% 
 Brushite- 2% 
Non Calcium Containing calculus 
 Uric acid – 7% 
 Struvite – 7% 
 Cystine -1% 
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Nephrolithiasis were classified on basis of metabolic 
derangements or any environmental abnormality. The derangements 
causing nephrolithiasis with calcium were due to hypercalciuria, 
hyperoxaluria, hyperuricosuria, and hypocitraturia. Cystine calculus 
was formed due defective absorption of renal cystine. Uric acid 
calculus was formed in acidic urine and Struvite calculus formed in 
infective urine where urea splitting organisms like Proteus and 
Klebsiella cause urine alkalization and calculus formation. For 
Cystine calculus treatment will be started immediately knowing the 
chemical composition of the calculus. But in calcium containing 
calculi, causes were multiple so it was important to understand the 
underlying metabolic disorders causing the calculus to start the 
appropriate treatment   
Calcium containing calculus 
Hypercalciuria 
  Hypercalciuria was one of the most frequently detected 
abnormalities found in persons having calcium containing 
nephrolithiasis. The pathogenic role for hypercalciuria in 
nephrolithiasis were: 1) in approximately 36% to 66% of 
individuals with calculus, hypercalciuria was present, 2) medical 
therapy tends to fail if the patient had persistent hypercalciuria, 
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3)therapies which reduces urinary calcium level also reduces 
calculus formation, 4) increased urinary calcium found in patients 
with nephrolithiasis with Randall’s plaque and it was thought as a 
precursor of calcium calculus. Increased calcium concentrations in 
urine causes increased urinary calcium salts saturation and reduced 
urinary calculus inhibitors like urinary citrate.  
Pak et al36 classified the causes of hypercalciuria into three 
types  
 Absorptive hypercalciuria   
 Renal hypercalciuria  
 Resorptive hypercalciuria   
Absorptive Hypercalciuria was defined as increased urinary 
calcium following oral calcium load due to increased intestinal 
absorption of calcium. It usually occurs in 55% of calculus forming 
patients. It was classified into type 1- when urinary calcium 
excretion was high in spite of low calcium diet and type 2- when 
urinary calcium level becomes normal when patient was placed in 
calcium restricted diet. 
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Renal hypercalciuria 
Of the reabsorbed 98% of filtered calcium, 70% of the 
absorption occurs in proximal tubule mostly by paracellular 
pathway. So impaired renal absorption leads to increased urinary 
calcium leads to secondary hyperparathyroidism. The exact cause 
of renal calcium leak was not found but may be due to renal 
injuries, structural abnormality or functional defect. 
Resorptive Hypercalciuria 
It was uncommon and mostly due to primary 
hyperparathyroidism. Primary hyperparathyroidism was responsible 
for the formation of nephrolithiasis in 3-5% of cases37. Due to 
increased parathyroid hormone there was increased bone resorption  
and  increased urinary calcium .It also causes increased 1,25(OH)2 
vitamin D synthesis which in turn increases intestinal calcium 
absorption and  increases serum and urinary calcium. Primary 
hyperparathyroidism was suspected in nephrolithiasis when serum 
calcium levels were more than 10.1mgs%. In equivocal cases of 
serum calcium, ionized calcium and urinary cyclic AMP were 
measured (both increased in primary hyperparathyroidism).   
Resorptive hypercalciuria also caused by hypercalcemia of 
malignancy, vitamin D toxicity, sarcoidosis, and thyrotoxicosis. 
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Hyperoxaluria 
It was defined when urinary oxalate excretion exceeds 
40mg/day. Hyperoxaluria38 divided into  
1) Primary hyperoxaluria - when it was caused by genetic 
defect in the glyoxalate metabolism, where normal 
metabolism of glyoxalate to glycine does not happen and 
there is increased oxidative conversion of glyoxalate to 
oxalate occurs. It leads to increased (>100mgs/day) excretion 
of urinary oxalates. Primary hyperoxaluria divided in to three 
types according to the defect. In type 1 the enzyme defect was 
alanine glyoxylate aminotransferase (AGT) in liver and the 
patient have increased levels of oxalate and glycolate. In type 
2 the enzyme defect was glyoxylate reductase / 
hydroxypyruvate reductase (GRHPR) in liver and increased 
formation of L glyceric acid and oxalates. It was less severe 
form when compared to type 1. In type 3 no enzyme defect 
isolated till date. 
2) Enteric hyperoxaluria - when it was caused by intestinal 
malabsorbtive state as in inflammatory bowel disease, celiac 
sprue, intestinal resection surgeries or in bariatric surgeries 
done for obesity. It was the most common acquired form of 
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hyperoxaluria. Here due to malabsorption of fat, there was 
increased saponification of fatty acid with calcium and 
magnesium leading to decreased availability of calcium to 
complex with oxalate in intestine. So increased amount of 
oxalates were absorbed. 
3) Dietary hyperoxaluria- Diets rich39 in oxalates like nuts, 
spinach, strawberry, chocolate, broccoli and rhubarb can 
cause hyperoxaluria. Food with increased animal protein 
causes increase in urinary oxalate and calcium. Ascorbic acid 
addition in diet may convert in to oxalates in vivo and 
increase in urinary oxalates. Calcium restricted diet causes 
increased oxalate availability in bowel and causes increased 
urinary oxalate. When there was absent or reduced intestinal 
colonization of oxalate degrading bacterium (Oxalobacter 
formigenes) it may lead to increased urinary excretion of 
oxalates. 
Hyperoxaluria causes increased saturation of urinary calcium 
oxalate and leads to calcium oxalate calculus formation. Oxalate 
was said to cause crystal growth and crystal retention by renal 
tubular injury caused by lipid peroxidation and oxygen free radical 
formation. 
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Hyperuricosuria  
It was defined as when uric acid excretion40 in urine exceeds 
600mgs/day. Only hyperuricosuria   as an abnormality was noted in 
10% of calcium calculus forming patients without any other 
abnormalities.  At PH above 5.5 hyperuricosuria causes increased 
formation of calcium oxalate calculus by heterogeneous nucleation. 
At PH below 5.5 hyperuricosuria causes precipitation of uric acid 
crystals and formation of uric acid calculus by homogenous 
nucleation and calcium oxalate stones by heterogeneous 
precipitation. Hyperuricosuria reduces the effectiveness of urinary 
inhibitors of calculus formation by binding to urinary 
glycosasminoglycan like heparin. The common causes of 
hyperuricosuria were increased purine intake in diet, gout, 
myeloproliferative disorder, lymphoproliferative disorder, multiple 
myeloma, pernicious anaemia, polycythemia, thalassemia, partial or 
complete deficiency of enzyme hypoxanthine guanine 
phosphoribosyl transferase, enzyme phosphoribosylpyrophosphate 
synthetase overactivity and renal hypouricemia.  
Hypocitraturia  
It was defined as when urinary citrare level was below 
320mgs/day. Hypocitraturia  was present in 20% to 60% in calcium 
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calculus formers with other associated abnormalities and  in 10% as 
an isolated abnormality. Urinary excretion of citrate41 was 
primarily determined by acid base state of the body. Metabolic 
acidosis causes enhanced renal tubular absorption and decreased 
citrate synthesis in peritubular cells leading to decreased urinary 
citrate level. Hypocitraturia was caused by pathological states of 
acidosis as in distal tubular acidosis, chronic diarrhea state and 
excessive animal protein ingestion.  
Distal renal tubular acidosis44 was associated with high 
urinary PH (>6.5), high serum chloride and low level of serum 
potassium and bicarbonate.  Acidosis increases bone resorption and 
increased renal leak of calcium.There was increased excretion of 
calcium and phosphate and decreased urinary citrate level favoring 
calcium phosphate calculus formation. It was confirmed by oral 
acid load test (ammonium chloride test) as these patients were 
unable to acidify urine (< 5.5). In chronic diarrhea there was 
increase intestinal loss of alkali leading to acidosis and subsequent 
hypocitraturia. Increase animal protein intake causes increased acid 
production and hypocitraturia. Drugs like thiazide diuretics causes 
increase in intracellular acidosis and hypokalemia and 
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hypocitraturia, Enalapril causes hypocitraturia, acidosis and 
hypokalemia. 
Hypomagnesuria  
It was associated with other abnormalities in 6% to 11% 
patient with calculus disease and as an isolated abnormality in 1%.  
It acts as an inhibitor of calculus formation by complexion with 
calcium and oxalate salts and also by increasing urinary citrate 
level. Hypomagnesuria was caused by decreased intake in diet and 
increased loss in chronic diarrhea disorders. 
Uric acid stones 
Uric acid stones40 were caused by three main determinants. 
They were low urine volume, low PH and hyperuricosuria. Of these 
low urinary PH was very important and consistent variable for the 
formation of uric acid calculus. Uric acid calculus forms due to 
congenital, acquired or idiopathic causes. Congenital causes were 
disorders involving renal tubular urate transport and uric acid 
metabolism causing hyperuricosuria. Acquired causes were chronic 
diarrhea, increased animal protein intake and intake of uricosuric 
drugs and volume depletion. Patients with gouty diathesis have 
idiopathic low urinary PH and decreased fractional excretion of uric 
acid and do not have gout.  
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The pathogenesis of low urinary PH in idiopathic uric acid 
calculi was not entirely known and it may be multifactorial. Sakhee 
et al42 first noted that normouricosuric patients with  pure uric acid 
calculus were likely to  have  type 2 diabetes mellitus or had 
glucose intolerance when compared to normal persons or patients 
having mixed calculus. Further studies shows that uric acid calculus 
formers excrete more acid in urine and less citrate in urine. The 
insulin resistance state was linked to the disorder of ammonium 
excretion in uric acid stone formers.  
Pak et al 43 observed higher prevalence of low urinary pH and 
uric acid calculus in type 2 diabetes mellitus. The mechanism of 
low urinary pH produced by insulin resistance was not completely 
known. Insulin has been shown to promote ammonia genesis in 
kidney from the substrate glutamine and to stimulate Na+/H+ 
exchanger in the proximal tubule (responsible for ammonium 
transport or trapping in urine). In insulin resistance state there will 
be impaired ammonium production and excretion, so hydrogen ion 
in urine was un buffered leading to low urinary pH. Other 
mechanism stated was increased free fatty acid in the blood in 
diabetes would compete with alpha ketoglutarate(end product of 
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glutamine metabolism) for entry into Krebs cycle and reduces 
ammonium production.  
Normally there will be alkalization of urine and blood in 
morning and after meals and was called alkaline tide. Loss of 
diurnal variation in urinary pH occurs in insulin resistance state and 
this may cause persistence low urinary pH and uric acid calculus. 
Acidic pH in urine was promoted by increased endogenous acid 
production and by dietary means. Net acid excretion (NAE) was 
high in uric acid calculus formers with type 2 diabetes mellitus than 
in normal persons after controlling dietary component. These 
studies show that there was increased acid production as a result of 
insulin resistance and obesity. The diet content influences urinary 
pH. Diet rich in animal protein causes acidic urine with increased 
excretion of undissociated uric acid and decreased excretion of 
citrate. Uric acid in urine was supersaturated by conditions 
lowering the urine volume like in individuals exposed to hot 
climate and in workers working in high temperature. 
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Cystine calculus 
It was caused by cystinuria45 which was an inherited 
autosomal recessive disease caused by disorder in intestinal and 
renal tubular transport of cystine, ornithine, lysine and arginine. 
Cystine was a dimer and was less soluble than its monomer 
cysteine. Cystine calculus was rare and accounts to less than 1% of 
total calculus disease. Cystine crystallization was caused by super 
saturation and there was no inhibitor for cystine calculus formation. 
Struvite calculus 
Struvite or magnesium ammonium phosphate calculus was 
discovered by Swedish geologist and named it as struvite after his 
mentor H.C.G.Von Struvite. It was formed as a result of urinary 
infection with urea splitting enzyme urease containing organism 
such as Proteus. Strvite or triple calculus occurs more commonly in 
females in the ratio of 2:1 when compared to males. It also occur in 
patients with increased risk of infection such as elderly, diabetic 
patients, infants born with congenital urinary tract abnormalities, in 
those with urinary stasis as a result of urinary tract obstruction, 
urinary diversion or neurological disorder.  
Spinal cord injury46 patients were increased risk of 
developing infective calculus and calcium calculus because of 
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neurogenic urinary bladder and hypercalciuria due to immobility. 
The other calculi were Xanthine and dihydroxyadenine calculus, 
matrix calculus, Ammonium acid urate calculus and medication 
induced calculus. Medication induced calculus was divided into 
medication that directly promotes calculus formation due to excess 
ingestion like indinavir, triamterene, guaifenesin, silicate, 
ciprofloxacin and  drugs that promote calcium calculus formation 
such as furosemide, acetazolamide, bumetanide. Patients with 
anatomical anomalies associated with urinary obstruction were 
prone to develop calculus disease. In ureteropelvic junction 
obstruction the chance of developing urinary calculus was about 
20%. In Horse shoe kidneys the chance of getting nephrolithiasis 
was high due to impaired renal drainage caused by high insertion of 
ureter and also presence of metabolic derangements especially 
hypocitraturia. Calculus formation occurs in 40% of calyceal 
diverticulum patients. Medullary sponge kidney was a disorder 
having ectasia collecting ducts of kidney. It was associated with 
nephrocalcinosis and nephrolithiasis in most of the patients. 
METABOLIC SYNDROME 
Metabolic syndrome was combination of medical disorders 
when it occurs together then there was increased risk of developing 
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diabetes mellitus or cardiovascular disease3 . It was also called as 
Syndrome X, Insulin resistance syndrome or Reaven’s syndrome47 
(named after Gerald Reaven). In his lecture in 1988, he introduced 
the term ‘Syndrome X’ in describing insulin resistance syndrome. 
Prevalence of metabolic syndrome increases with age and it drives 
the global epidemic of cardiovascular disease and type 2 diabetes 
mellitus.  Metabolic syndrome was defined by some sets of defining 
criteria by two sources. 
A) The International Diabetic Federation (IDF)48 criteria 
B) National Cholesterol Education Program(NCEP)49 criteria 
The defining criteria were similar in both groups except of 2 
differences. IDF states that if body mass index was more than 30, 
central obesity was assumed and no need for measurement of waist 
circumference, where as NCEP criteria measures waist 
circumference for measuring obesity. Also IDF uses geography 
specific variable cut off points for waist circumference while NCEP 
uses one cut off point for waist circumference measurement regard 
less of geography of study. 
IDF criteria for defining metabolic syndrome were central 
obesity defined by waist circumference with ethnic specific values 
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and any two of following: Raised blood pressure: systolic BP >130 
mmHg or diastolic BP > 85mm Hg or known hypertensive on 
treatment, Raised fasting blood sugar >100mg/dl or known diabetic 
on treatment , Raised triglycerides >150mg/dl and reduced serum 
HDL cholesterol  <40mg/dl in males and <50mg/dl in females or 
known lipid abnormality patient on treatment. 
American Heart Association and National Heart Lung and 
Blood Institute (AHA/NHLBI) 50 intended to update NCEP ATP III 
definition of metabolic syndrome and defined metabolic syndrome 
as the presence of any of the three criteria: 
1) Waist- circumference ≥102 cms in males and ≥ 88 cms in 
females  
2) Serum- triglycerides >150mgs/100ml or on treatment for 
lipid disorders 
3) Serum-cholesterol <40mgs/dl and <50mgs/dl in women or on 
treatment   
4) Systolic- blood pressure ≥130 mm of Hg or diastolic- blood 
pressure≥ 85 mm of Hg or on any anti-hypertensive drug   
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5) Fasting blood sugar ≥100mgs/dl or on any anti diabetic 
drugs for diabetes mellitus. 
Metabolic syndrome and its components were associated with 
nephrolithiasis. The pathophysiology of this association was not 
clearly understood, but metabolic syndrome was associated with 
urinary constituents’ changes like decreased citrate, low urinary pH 
and increased excretion of calcium and uric acid in urine. These 
changes lead to formation of calcium and uric acid calculus.  
Asplin J R51 et al had observed increased prevalence of 
obesity in USA due to increased food intake and decreased physical 
activity. They concluded that there was increased incidence of 
nephrolithiasis in obese patients. They proposed the causes of this 
increased incidence can be due to increased amount of calculus 
forming constituents in diet and altered kidney acid base 
metabolism. Weight loss procedures done for treatment of obesity 
have risk of calculus formation. Low carbohydrate diet causes risk 
of uric acid and calcium containing calculus formation. Bariatric 
procedures done for obesity have risk of developing calcium 
oxalate calculus due to hyperoxaluria. So controlled weight 
reduction should be carried out to prevent this complication. 
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Taylor EN et al52 observed increased prevalence of 
nephrolithiasis in obese patients. They showed relative risk of 
developing calculus in males over   100kgs was 1.44 when compared 
to male weighing less than 68kgs. Also obese females have increased 
relative risk of 1.89 comparing non obese individuals. 
Negri AL et al53 in their study on evaluation of calculus 
forming constituents in urine in calculus patients found that in 
obese and over weight patients there was increased excretion of 
uric acid and oxalates and they have increased risk of developing 
nephrolithiasis when compared to non-obese persons. They also 
observed increase in body mass index as age advances in males and 
female individuals. 
Cappuccino FP et al54 in their prospective study in southern 
Italy had showed that there was increased incidence of 
nephrolithiasis in middle aged males and females with systemic 
hypertension. The real mechanism of calculus formation in 
hypertensive patients was not well understood. Borghi L et al 55 
observed essential hypertensive patients excretes increased amount 
of calcium, uric acid, oxalate in urine in males. Female essential 
hypertensive persons excretes increased amount of calcium, 
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phosphorus, uric acid in their urine. They have increased propensity 
to form calcium oxalate and calcium phosphate calculus. The 
causative factors may be due to excessive consumption of animal 
protein and salts or may be due to overweight. 
Iba A et al 56 in their study on a rat model of metabolic 
syndrome had observed that insulin resistance and metabolic 
syndrome increases the propensity to form uric acid calculus and 
also calcium calculus. They noted in their rat model with the 
increase in body weight, serum triglycerides, blood sugar and 
insulin there is increased urinary excretion of calcium and uric 
acid. They also noted there is decreased excretion of citrate in urine 
with low urinary pH. 
Kadlec AO et al57 evaluated difference in calculus 
composition due to metabolic syndrome in a retrospective analysis. 
They found that there is increased incidence of uric acid calculus 
and very low incidence of calcium phosphate calculus in patients 
having metabolic syndrome. Morbid obese patients tend to form 
calcium oxalate calculus. Inci M et al58 in their analysis had shown 
that increased body mass index and elevated serum triglycerides  
and reduced serum HDL which were components of metabolic 
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syndrome were associated with increased uric acid and calcium 
oxalate dihydrate-calcium oxalate monohydrate calculus.  
Abate N et al59 evaluated the association of uric acid 
nephrolithiasis with insulin resistance occurring in metabolic 
syndrome. He concluded that there was decreased ammonia genesis 
in kidney leading to decreased urinary pH in insulin resistance 
patients which promotes uric acid calculus formation in normal uric 
acid excreting patients.    
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        MATERIAL AND METHODS 
TITLE OF THE STUDY 
A study of association between metabolic syndrome and 
nephrolithiasis 
PLACE OF THE STUDY 
The study was conducted in the Department of Urology, Madras 
Medical College, Rajiv Gandhi Government General Hospital, 
Chennai-3 with the collaboration of Barnard Institute of Radiology, 
Madras Medical College, Rajiv Gandhi Government General 
Hospital, Chennai- 3 and Institute of Biochemistry, Madras Medical 
College, Rajiv Gandhi Government General Hospital, Chennai-3. 
STUDY DESIGN 
Single centre. Prospective case control study. 
PERIOD OF STUDY 
The study work was carried out from March 2012 to February 
2013.  
ETHICAL COMMITTEE APPROVAL 
The institutional Ethical Committee review board approved 
this study. 
No. 25032012.  
 36 
INCLUSION CRITERIA 
Cases: 
Patients with unilateral or bilateral renal calculus  
Controls:  
Individuals without renal calculus 
EXCLUSION CRITERIA 
Cases: 
 Patients with congenital renal abnormalities 
 Acute or Chronic renal failure patients 
 Patients with metabolic bone disorder or taking treatment for 
osteoporosis 
 Patients with gout 
 Patients with major debilitating disease like cancer 
 Patients with complication of calculus disease like Calculus 
pyelonephritis, pyonephrosis or perinephric abscess  
 Pregnancy  
 Patients with contracted kidney 
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Controls: 
    Patients with previous history of nephrolithiasis and other 
criteria’s are as for the cases. 
SAMPLE SIZE 
100 cases (Group 1) and 100 control (group 2) patients. 
METHOD OF STUDY 
Details of the study explained to each and every cases and 
control patients. Informed consent obtained from all of the cases 
and control. Patients were evaluated in detail. The details obtained 
from the patients were recorded in the proforma.  Analysis was 
done with the collected details prospectively. 
PATIENT EVALUATION  
All the individuals (both the cases and controls) underwent 
ultrasound evaluation of both kidneys. Nephrolithiasis was 
diagnosed in ultrasonogram by the appearance of hyperechoic 
lesion in the pelvic calyceal system of kidney followed by post 
acoustic shadow. These patients were included in group 1(cases). 
Patients without nephrolithiasis were included in group 2 
(controls). Both groups undergo evaluation for the presence of 
metabolic syndrome. All cases and control undergo measurement of 
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waist circumference, their systolic and diastolic blood pressure. 
Their fasting blood analysed for blood sugar, serum triglycerides 
and serum HDL cholesterol levels. These details were entered into 
proforma and analysed.  
METHODOLOGY  
Ultrasonogram 
All patients including all cases and control patients undergo 
ultrasonogram using Mind Ray machine with 5MHz probe. The 
presence of calculus was defined by hyperechoic lesion in the 
pelvic calyceal system followed by post acoustic shadow.   
Waist circumference 
Waist circumference was measured using a non stretchable 
measuring plastic tape. The measurement was taken with the 
individuals in a relaxed and standing position with both feet 
together. Waist circumference measured at midpoint of lowermost 
border of twelfth rib and upper border of iliac crest at the end of 
expiration. 
Measurement of Blood Pressure 
Systolic and diastolic BP was measured using Diamond 
Deluxe sphygmomanometer. Blood pressure was obtained with the 
individuals in calm and sitting position. Two readings were taken 
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with five minutes apart and their average was taken into 
consideration. 
NORMAL RENAL ULTRASONOGRAPHY 
 
 
ULTRASOUND SHOWING NEPHROLITHIASIS 
 
CALCULUS 
POST ACOUSTIC SHADOW 
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BIOCHEMICAL TESTS 
Fasting venous blood was taken after over night fasting from 
both cases and control individuals. Plasma fasting sugar was 
measured by Trinder’s glucose activity test or glucose oxidase and 
peroxidase method using semi auto analyzer – Optima S. Serum 
triglyceride was measured by Calorimetric analysis using enzymatic 
analysis by GPO- PAP method using semi auto analyzer Optima S. 
Serum HDL cholesterol was measured by using direct HDL 
cholesterol kit by Clearance method using semi auto analyzer 
OptimaS.  
The defining criteria used were based on AHA/NHLBI 
criteria formed in 2004. The IDF gives Ethnic specific values for 
the measurement of waist circumference. The cut off point for 
south Asians were 90 cms for male and 80 cms for female60. The 
presence of metabolic syndrome was defined by presence of 3 or 
more positive points in the below criteria’s: 
1) Waist- circumference ≥ 90 cms in males and ≥ 80 cms in 
females  
2) Serum- triglycerides > 150mgs/100ml or on treatment for 
lipid disorders 
 41 
3) Serum-cholesterol <40 mgs/100ml in males and 
<50mgs/100ml in females or on treatment for high 
cholesterol.  
4) Systolic- blood pressure ≥130 mm of Hg or diastolic- blood 
pressure ≥ 85 mm of Hg or on any anti hypertensive drug   
5) Fasting –serum- glucose ≥100mgs/100ml or on any drug 
treatment for diabetes mellitus. 
Metabolic syndrome presence in nephrolithiasis group (cases) 
was compared with metabolic syndrome in normal individuals 
(controls). Again each component of metabolic syndrome was 
compared with cases and control. 
STATISTICAL METHOD 
For discrete data -proportion is computed and the mean and 
standard deviation are computed for the continuous data.  
The chi square test was applied to compare the proportions 
between the groups to assess the statistical significance.   
All analyses were two tailed and p <0.05 was considered 
significant.  
SPSS version 16.0 was used for data analysis.  
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RESULTS AND OBSERVATIONS 
DESCRIPTIVE STATISTICS 
Our study consists of 200 individuals who visited our hospital 
during March 2012 to February 2013. 100 patients were cases (Group 1) 
with nephrolithiasis and were confirmed by ultra sonogram. Controls 
(Group 2) were 100 normal persons without nephrolithiasis as confirmed 
by ultra sonogram or patients with other diseases like urethral stricture, 
prospective renal donors and urinary tract infections without any 
evidence of nephrolithiasis in ultra sonogram.  
Table-1: The patient characteristics in two groups were shown in 
Group Statistics 
 Group Number Mean Std. Deviation P-value 
Case 100 38.2500 9.67385 Age 
 Control 100 35.6200 10.99015 
0.074 
Case 100 1.584 0.5120 Stone 
Size Control 100 NA  
NA 
P-value <0.05 was significant. 
The Mean age group of control (Group 2) was 35.62 + 
10.99years. The mean age group of cases (Group 1) was 38.25+9.67 
years. Age group between cases and control was comparable and 
was statistically insignificant (P value >0.05). 
In Group 1 (cases) there were 47 females and 53 males. In 
Group 2(controls) there were 48 females and 52 males. 
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Table: 2 - Gender difference between two groups  
SEX 
   
Male Female 
Total 
Count 53 47 100 Case 
% within Group 53.0% 47.0% 100.0% 
Count 52 48 100 
Group 
Control 
% within Group 52.0% 48.0% 100.0% 
Count 105 95 200 Total 
% within Group 52.5% 47.5% 100.0% 
Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. (2-
sided)(P-
value) 
Exact 
Sig. (1-
sided) 
Pearson Chi-Square .020a 1 .887   
Continuity 
Correction b .000 1 1.000 
  
Likelihood Ratio .020 1 .887   
Fisher's Exact Test    1.000 .500 
Linear-by-Linear 
Association .020 1 .888 
  
N of Valid Cases b 200     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 47.50. 
b. Computed only for a 2x2 table 
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The gender difference between two groups was comparable 
and was statistically insignificant (P-value> 0.05). (Fig: 1&2) 
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 INTER GROUP COMPARISON  
By AHA/NHLBI criteria for metabolic syndrome with Ethnic 
specific cut off for waist circumference, the number of patients 
with metabolic syndrome in Group 1 (Cases) was 42(42%) and  in 
Group 2(Control) it was 26(26%) .(Fig: 3) 
 
 
The metabolic syndrome in two groups were compared by chi 
square test for test for significance 
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Table – 3: Metabolic Syndrome  
Metabolic 
Syndrome group 
   
Yes No 
Total 
Count 42 58 100 Case 
% within Group 42.0% 58.0% 100.0% 
Count 26 74 100 
Group 
Control 
% within Group 26.0% 74.0% 100.0% 
Count 68 132 200 Total 
% within Group 34.0% 66.0% 100.0% 
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Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided)(P-
value) 
Exact 
Sig. (1-
sided) 
Pearson Chi-Square 5.704a 1 .017   
Continuity 
Correction b 5.013 1 .025 
  
Likelihood Ratio 5.744 1 .017   
Fisher's Exact Test    0.025 0.012 
Linear-by-Linear 
Association 5.676 1 .017 
  
N of Valid Cases b 200     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 34.00. 
b. Computed only for a 2x2 table 
Here the proportion of metabolic syndrome was significantly 
(P-value <0.05) higher (46% Vs 24%) in Cases when compared to 
Control. So patients with metabolic syndrome has higher chances of 
getting nephrolithiasis  
The components of metabolic syndrome were waist 
circumference, blood pressure, fasting blood sugar, serum 
triglycerides and serum high density lipoprotein. Each component 
of the metabolic syndrome was compared between cases (Group 1) 
and control (Group 2). The proportion of each component of 
metabolic syndrome was given in Table: 4. and in Fig: 4. 
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Table: 4- Distribution of basic characteristics and abnormalities 
of metabolic syndrome components by Case and control 
Variabble Case(N=100) Control( N=100) P-value 
Mean Age 38.2±9.67 35.6±10.9 0.074 
Mean Stone size 1.58±0.51 - - 
SEX 
Male(%) 53 52 
Female(%) 47 48 
1.000 
ABNORMALITIES 
WC(%) 52 31 0.004 
BP(%) 47 23 0.001 
FBS(%) 33 21 0.079 
TGL(%) 34 28 0.445 
HDL(%) 29 25 0.633 
Metabolic syndrome(%) 42 26 0.025 
P-value<0.05 was significant. TGL-Triglycerides, HDL- High 
density lipoprotein, WC-Waist Circumference, BP- Blood Pressure, 
FBS- Fasting Blood Sugar. 
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WC-waist circumference, BP-blood pressure, FBS-fasting blood sugar,  
TGL-triglycerides, HDL-high density lipoprotein 
 
All components of metabolic syndrome were increased in 
cases when compared to control. Waist circumference component 
was 52% in cases and 31% in control. Blood pressure component 
was 47% in cases and 23% in control. Fasting blood sugar 
component was 33%in cases and 21% in control. Serum 
triglycerides were 34%in cases and 28% in control. Serum HDL 
was 29% in cases and 25% in control. Each component was tested 
separately for significance by chi square test.  
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WAIST CIRCUMFERENCE 
The waist circumference component accounts to 52% in 
nephrolithiasis (cases) and 31% in control group and were tested 
for significance. (Table: 5) 
Table: 5- Waist Circumference group 
Waist Circumference group 
   Normal 
(m<90cm, 
f<80cm) 
Abnormal 
(m>=90cm, 
f>=80cm) 
Total 
Count 48 52 100 Case 
% within 
Group 48.0% 52.0% 100.0% 
Count 69 31 100 
Group 
Control 
% within 
Group 69.0% 31.0% 100.0% 
Count 117 83 200 Total 
% within 
Group 58.5% 41.5% 100.0% 
Normal - <90cm in Males, <80cm in Females. 
Abnormal - > 90cm in Males, > 80cm in Females 
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Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-Square 9.082a 1 .003   
Continuity 
Correction b 8.238 1 .004 
  
Likelihood Ratio 9.161 1 .002   
Fisher's Exact Test    0.004 0.002 
Linear-by-Linear 
Association 9.037 1 .003 
  
N of Valid Cases b 200     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 41.50. 
b. Computed only for a 2x2 table 
The proportion of waist circumference component was 
significantly (P-value < 0.05) higher (52%Vs31%) in cases when 
compared to control. 
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BLOOD PRESSURE COMPONENT 
The Blood pressure component accounts to 47% in 
nephrolithiasis (cases) and 23% in control group and were tested 
for significance. (Table: 6) 
Table: 6 Blood Pressure component group 
Blood Pressure group 
   Normal 
(sbp<130|dbp 
<85mm/Hg) 
Abnormal 
(sbp>130|dbp 
>85mm/Hg) 
Total 
Count 53 47 100 Case 
% within 
Group 53.0% 47.0% 100.0% 
Count 77 23 100 
Group 
Control 
% within 
Group 77.0% 23.0% 100.0% 
Count 130 70 200 Total 
% within 
Group 65.0% 35.0% 100.0% 
sbp-systolic blood pressure, dbp- diastolic blood pressure 
Normal- Sbp <130mmHg, dbp <85mmHg 
Abnormal- Sbp >130mmHg, dbp > 85mmHg  
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 12.659a 1 .000 
  
Continuity 
Correction b 11.626 1 .001 
  
Likelihood Ratio 12.854 1 .000   
Fisher's Exact Test    0.001 .000 
Linear-by-Linear 
Association 12.596 1 .000 
  
N of Valid Cases b 200     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 35.00. 
b. Computed only for a 2x2 table, sbp-systolic blood pressure, dbp- diastolic blood pressure 
The proportion of blood pressure component was 
significantly (P-value<0.05) higher (47%Vs23%) in nephrolithiasis 
(cases) group compared to control group. 
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FASTING BLOOD SUGAR COMPONENT 
The Fasting Blood sugar component accounts to 33% in 
nephrolithiasis (cases) and 21% in control group and were tested 
for significance. (Table: 7) 
Table: 7- Fasting Blood Sugar group 
Fasting  
Blood Sugar group 
   
Normal 
FBS  
<100 mg/dl 
Abnormal 
FBS  
>100  mg/dl 
Total 
Count 67 33 100 Case 
% within Group 67.0% 33.0% 100.0% 
Count 79 21 100 
Group 
Control 
% within Group 79.0% 21.0% 100.0% 
Count 146 54 200 Total 
% within Group 73.0% 27.0% 100.0% 
FBS- Fasting Blood Surgar  
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Chi-Square Tests 
 Value df 
Asymp. 
Sig.  
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 3.653a 1 .056   
Continuity 
Correction b 3.070 1 .080 
  
Likelihood Ratio 3.676 1 .055   
Fisher's Exact Test    0.079 0.040 
Linear-by-Linear 
Association 3.635 1 .057 
  
N of Valid Cases b 200     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 27.00. 
b. Computed only for a 2x2 table 
In fasting blood sugar component, though it was not 
statistically (P-value>0.05) significant, the proportion of elevated 
fasting blood sugar was relatively higher (33%Vs21%) in the cases.   
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SERUM TRIGLYCERIDES COMPONENT 
The serum triglycerides’ component accounts to 34% in 
nephrolithiasis (cases) and 28% in control group and were tested 
for significance. (Table: 8) 
Table: Serum TGL group 
Serum TGL group 
   
Normal 
<150mg/dl 
Abnormal 
>=150 mg/dl 
Total 
Count 66 34 100 Case 
% within Group 66.0% 34.0% 100.0% 
Count 72 28 100 
Group 
Control 
% within Group 72.0% 28.0% 100.0% 
Count 138 62 200 Total 
% within Group 69.0% 31.0% 100.0% 
TGL- Triglycerides 
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Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square .842a 1 .359   
Continuity 
Correction b .584 1 .445 
  
Likelihood Ratio .843 1 .359   
Fisher's Exact Test    0.445 0.222 
Linear-by-Linear 
Association .837 1 .360 
  
N of Valid Cases b 200     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 31.00. 
b. Computed only for a 2x2 table 
Though here in the serum triglycerides component was not 
statistically (P-value >0.05) significant, the proportion of elevated 
serum triglycerides component was relatively higher in the cases.  
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SERUM HDL COMPONENT 
The serum HDL component accounts to 29% in 
nephrolithiasis (cases) and 25% in control group and were tested 
for significance. (Table: 9) 
Table: 9 - Serum HDL group 
Serum HDL group 
   
Normal (m<=40| 
f<=50mg/dl) 
Abnormal 
(m>40| f>50 
mg/dl) 
Total 
Count 71 29 100 Case 
% within 
Group 71.0% 29.0% 100.0% 
Count 75 25 100 
Group 
Control 
% within 
Group 75.0% 25.0% 100.0% 
Count 146 54 200 Total 
% within 
Group 73.0% 27.0% 100.0% 
HDL- High Density Lipoprotein 
m- Male, f- Female. 
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Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square .406a 1 .524   
Continuity 
Correction b .228 1 .633 
  
Likelihood Ratio .406 1 .524   
Fisher's Exact Test    .633 .317 
Linear-by-Linear 
Association .404 1 .525 
  
N of Valid Cases b 200     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 27.00. 
b. Computed only for a 2x2 table 
Though here in the serum HDL component was not 
statistically (P-value >0.05) significant, the proportion of serum 
HDL component was relatively higher in the cases.  
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DISTRIBUTION OF METABOLIC COMPONENTS BY 
GROUPS 
The groups with nephrolithiasis (cases) and the controls were 
cross tabulated by distribution of the components of metabolic 
syndrome and this was tested for significance. (Table: 10) 
Table:10 - Syndrome 
syndrome 
   
0 1 2 3 4 5 
Total 
Count 30 14 14 19 19 4 100 Case 
% 
within 
Group 
30.0% 14.0% 14.0% 19.0% 19.0% 4.0% 100.0% 
Count 42 21 11 19 7 0 100 
Group 
Control 
% 
within 
Group 
42.0% 21.0% 11.0% 19.0% 7.0% .0% 100.0% 
Count 72 35 25 38 26 4 200 Total 
% 
within 
Group 
36.0% 17.5% 12.5% 19.0% 13.0% 2.0% 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 13.298a 5 .021 
Likelihood Ratio 15.079 5 .010 
Linear-by-Linear 
Association 9.476 1 .002 
N of Valid Cases 200   
a. 2 cells (16.7%) have expected count less than 5. The minimum expected count is 2.00. 
The proportion of more than three components of metabolic 
syndrome was significantly increased in cases group. There was a 
significant increasing trend was observed as the metabolic 
components increases in cases. This was statistically significant (P-
value<0.05) by linear by linear association. 
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DISCUSSION 
Nephrolithiasis is a common disorder affecting the urinary 
tract. The morbidity produced by nephrolithiasis to the patients and 
the huge amount spend on the diagnosis, treatment and follow up 
leads to search for preventive strategies of nephrolithiasis. 
Due to globalization of economy and increased availability of 
easy life style commodities there was increased prevalence of 
metabolic syndrome in our community. Gupta R et al61 on their 
population based study in north India showed that there is low 
prevalence of metabolic syndrome  during adolescence age and very 
rapid increase in metabolic syndrome prevalence above age of 
30.He called for urgent interventions to prevent epidemic of 
metabolic syndrome.  Sedentary life habit, increased intake of 
animal proteins and salted food and lack of exercise leads to 
obesity, hypertension, type two diabetes mellitus and dylipidemia. 
These causes increased risk of developing cardiovascular disease 
and nephrolithiasis. 
Sakhaee et al42 first described the association of diabetes 
mellitus with uric acid calculus formation in 2002. He suggested 
decreased ammonia formation in the kidney due to insulin 
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resistance was the cause of acidic urine and uric acid calculus 
formation. There were many international studies describing the 
association of metabolic syndrome with nephrolithiasis. Till date no 
study was available comparing this association in our part of the 
country. 
This study was conducted to evaluate the association of 
metabolic syndrome in nephrolithiasis patient population in our part 
of country. In this study patients with nephrolithiasis (Cases) was 
compared with persons without nephrolithiasis (Control) for the 
presence of metabolic syndrome. We also compared the association 
of individual component of metabolic syndrome between cases and 
controls. 
The present study demonstrated highly significant (P-
value<0.05) association of metabolic syndrome in nephrolithiasis 
patients when compared to control group (42% Vs 26%). Jeong IG62 
et al in their cross sectional study of 34,895 persons who underwent 
general health screening observed nephrolithiasis in 2.4%  and 
metabolic syndrome in 13.7% of the screened population. He 
demonstrated significant association of metabolic syndrome in 
nephrolithiasis group with OR of 1.25. Kim YJ et al63 demonstrated 
significant association of metabolic syndrome in the patients having 
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renal calculus (15.9% Vs 11%) when compared to individuals 
without renal calculus. Rendina D64 et al in their study of data’s of 
inpatients in southern Italy showed significant association of 
metabolic syndrome in renal calculus patients. He observed 
metabolic syndrome in 31% of the inpatient population. The present 
study also shows significant association in patient population. 
The present study shows significant association between 
components of metabolic syndrome with nephrolithiasis when 
compared with control. The metabolic component hypertension has 
statistically (P-value<0.05) significant association with 
nephrolithiasis (47% Vs 23%) when compared with control. This 
association was also observed by Kim YJ63 et al with a odd ratio of 
1.08 for males and 1.24 for females. Jeong IG62 et al observed 
statistic significance association between nephrolithiasis and 
increased waist circumference. In this study we demonstrated 
statistic significant (P-value<0.05) association of increased waist 
circumference (52% Vs 31%) between nephrolithiasis (cases) and 
control groups. 
Though there was no statistic significant association shown 
for increased fasting blood sugar, increased serum triglycerides and 
decreased HDL between cases and control, the proportions of these 
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components were high in nephrolithiasis group when compared to 
control. Taylor EN65 et al demonstrated increased incidence of 
nephrolithiasis in diabetes mellitus patients and was probably due 
to insulin resistance.  
Kohjimoto Y66 et al observed increased in metabolic 
syndrome traits with severity of renal calculus disease. We also 
observed increasing trends of components of metabolic syndrome in 
nephrolithiasis group. 
The present study has significant clinical implication in 
public health care in the prevention of formation of nephrolithiasis. 
Since metabolic syndrome prevalence is increasing in our 
community, it is very important to formulate policies to prevent and 
treat this syndrome. For the treatment of metabolic syndrome there 
were no randomized control trials oriented guidelines available. 
The initial treatments of metabolic syndrome were changes in 
lifestyle and diet modifications. Sedentary life style habits should 
be discouraged even from childhood. More activities should be 
included in the daily schedule like regular walking, minimum of 
thirty minutes exercise. Diets rich in fat or animal protein or salted 
foods should be restricted. Diets rich in vegetables, fruits, grains, 
legumes and low or no fat were encouraged. Controlled weight 
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reduction is advised in order to prevent increased risk of 
developing calculus by marked weight reduction programs like 
bariatric surgery. Pharmacological treatment for hypertension, 
diabetes and dyslipidemia can be taken for control of metabolic 
syndrome. 
The limitations of this study were stone composition in 
metabolic syndrome positive cases was not analysed, the change in 
urinary constituents in metabolic syndrome positive patients was 
not correlated, the duration of metabolic syndrome was not 
correlated with occurrence of   nephrolithiasis and was not a 
longitudinal study, so causal relationship is not established.           
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CONCLUSION 
The conclusions of this study are 
 Metabolic syndrome is significantly associated with 
nephrolithiasis 
 Of the components of metabolic syndrome a statistically 
significant association with nephrolithiasis is noted for 
increased waist circumference and hypertension.   
 In the present study the other three components of metabolic 
syndrome namely diabetes mellitus, increased serum 
triglycerides and decreased serum HDL were found to be 
statistically insignificant with regard to nephrolithiasis. 
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APPENDIX-1 
INFORMED CONSENT FORM 
Title of the study:  “A study of association between metabolic 
syndrome and nephrolithiasis” 
Name of the Participant:  
Name of the Principal (Co-Investigator): Dr.N.Suresh Kumar 
Name of the Institution: Rajiv Gandhi Govt General Hospital, 
Chennai – 3 
Documentation of the informed consent 
I _____________________________ have read the 
information in this form (or it has been read to me). I was free to 
ask any questions and they have been answered. I am over 18 years 
of age and, exercising my free power of choice; hereby give my 
consent to be included as a participant in” A study of association 
between metabolic syndrome and nephrolithiasis” 
1) I have read and understood this consent form and the 
information provided to me. 
2) I have had the consent document explained to me. 
3) I have been explained about the nature of the study. 
4) I have been explained about my rights and responsibilities by 
the investigator. 
5) I have been informed the investigator of all the treatments I 
am taking or have taken in the past 3 months including any 
native (alternative) treatment. 
6) I have been advised about the risks associated with my 
participation in this study. 
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7) I agree to cooperate with the investigator and I will inform 
him/her immediately if I suffer unusual symptoms. 
8) I have not participated in any research study within the past 6 
month(s) 
9) I am aware of the fact that I can opt out of the study at any 
time without having to give any reason and this will not 
affect my future treatment in this hospital.  
10) I am also aware that the investigator may terminate my 
participation in the study at any time, for any reason, without 
my consent. 
11) I hereby give permission to the investigators to release the 
information obtained from me as result of participation in this 
study to the sponsors, regulatory authorities, Govt. agencies, 
and IEC. I understand that they are publicly presented. 
12) I have understand that my identity will be kept confidential if 
my data are publicly presented 
13) I have had my questions answered to my satisfaction. 
14) I have decided to be in the research study. 
I am aware that if I have any question during this study, I 
should contact the investigator. By signing this consent form I 
attest that the information given in this document has been clearly 
explained to me and understood by me, I will be given a copy of 
this consent document. 
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For adult participants 
Name and signature / thumb impression of the participant (or legal 
representative if participant incompetent) 
Name _________________________ 
Signature_________________ Date________________ 
 
Name and Signature of impartial witness (required for illiterate 
patients): 
Name _________________________ 
Signature_________________ Date________________ 
  
  
Address and contact number of the impartial witness: 
__________________________________ 
Name and Signature of the investigator or his representative 
obtaining consent: 
Name _________________________ 
Signature_________________ Date________________ 
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ஆராய்ச்சி ஒப்புதல் கடிதம் 
சிறுநீரக கல் உள்ளவருக்கும் அனுேசபபிணி   உள்ளவருக்கும் 
(ெமடேபாலிக் சிண்ேறாம்)   உள்ள பிைணப்பு 
பற்றிய     ஆராய்ச்சி 
ெபயர் :      ேததி :  
வயது :      உள்ேநாயாளி எண் : 
பால் :      ஆராய்ச்சி ேசர்க்ைக 
எண் : 
 இந்த ஆராய்ச்சியின் விவரங்களும் அதன் ேநாக்கம்  
முழுைமயாக எனக்கு ெதளிவாக விளக்கப்பட்டது.  
 எனக்கு விளக்கப்பட்ட விஷயங்கைள நான் புரிந்து  
ெகாண்டு எனது சம்மதத்ைத ெதரிவிக்கிேறன். 
 சிறுநீரககல் உள்ளவருக்கும் அனுேசபபிணி  உள்ளவருக்
கும்(ெமடேபாலிக்சிண்ேறாம்)    உள்ள  பிைணப்பு பற்றிய    
ஆராய்ச்சிக்கு ேதைவயான அைணத்து விவரங்கைளயும்  
ெதரியபடுத்துவதற்கு முழு சம்மதம் ெதரிவிக்கிேறன். 
 இந்த ஆராய்ச்சியில் பிறரின் நிர்பந்தமின்ரி என் ெசாந்த 
விருப்பத்தின் ேபரில் தான் பங்குெபருகிேறன் மற்றும் இந்த 
ஆராய்ச்சியில் இருந்து எந்ேநரமும் பின் வாங்கலாம் 
என்பைதயும் அதனால் எந்த பாதிப்பும் ஏற்படாது என்பைதயும் 
நான் புரிந்து ெகாண்ேடன். 
நான் என்னுைடய சுய நிைனவுடனும் மற்றும் முழு  
சுதந்திரத்துடனும் இந்த மருத்துவ ஆராய்ச்சியில் என்ைன 
ேசர்த்துக்ெகாள்ள சம்மதிக்கிேறன். 
 இந்த ஆராய்ச்சியின் தகவல்கைளயும் முடிவுகைளயும்  
அறிவியல் ேநாக்கத்திற்காக பயன்படுத்துவதற்கு நான் 
அனுமதிக்கிேறன். நான் இந்த ஆராய்ச்சியில் பங்கு ெபற 
சம்மதிக்கிேறன். 
 
பங்ேகற்பவர் ெபயர் :    பங்ேகற்பவர்    ைகெயாப்பம் 
(அ) இடது கட்ைடவிரல் ேரைக  
 
ஆய்வாளர் ெபயர் : ஆய்வாளர் ைகெயாப்பம்  
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APPENDIX-2 
PROFORMA 
Name:       Age/Sex: 
IP /OP number:                         Occupation: 
Presence of nephrolithiasis: 
 
Waist circumference: 
Blood pressure: 
Blood fasting sugar: 
Serum triglycerides: 
Serum HDL: 
Inference: 
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APPENDIX-5 
ABBREVIATION 
 
CT  : Computed Tomography 
USG  : Ultrasonogram 
WC  : Waist Circumference 
FBS  : Fasting Blood Sugar 
SBP  : Systolic Blood Pressure 
DBP  : Diastolic Blood Pressure 
TGL  : Triglycerides 
HDL  : High Density Lipoprotein 
MSC  : Metabolic Syndrome Components 
S.No Group NAME AGEc SEX STONE SIDE STONE SIZE WAIST WC_gp SBP DBP BP_gp FBS FBS_gp TGL TGL_gp HDL HDL_gp TOTAL MSC
1 2 Arumugam 36 1 - - 106 1 120 84 0 88 0 168 1 36 1 3 3
2 2 Sakthivel 25 1 - - 83 0 110 70 0 82 0 120 0 46 0 0 0
3 2 Manoharan 49 1 - - 88 0 150 90 1 96 0 142 0 48 0 1 1
4 2 Kamala Kannan 33 1 - - 108 1 120 80 0 87 0 134 0 42 0 1 1
5 2 Selvi 40 2 - - 110 1 140 100 1 160 1 142 0 56 0 3 3
6 2 Gajendran 32 1 - - 82 0 120 80 0 90 0 130 0 48 0 0 0
7 2 Jeya kumar 42 1 - - 88 0 120 80 0 96 0 146 0 38 1 1 1
8 2 Rekha 26 2 - - 76 0 110 70 0 78 0 130 0 56 0 0 0
9 2 Laxmi 32 2 - - 96 1 120 80 0 89 0 138 0 54 0 1 1
10 2 Amudha 36 2 - - 102 1 140 92 1 156 1 140 0 60 0 3 3
11 2 Ramu 25 1 - - 86 0 120 70 0 92 0 132 0 48 0 0 0
12 2 Ragammal 65 2 - - 77 0 120 80 0 90 0 143 0 54 0 0 0
13 2 Saraswathi 40 2 - - 76 0 120 80 0 146 1 144 0 58 0 1 1
14 2 Kamala  32 2 - - 76 0 120 80 0 82 0 132 0 62 0 0 0
15 2 Gopi 28 1 - - 99 1 120 86 0 88 0 212 1 46 0 2 2
16 2 Prabhu 25 1 - - 80 0 110 70 0 86 0 136 0 42 0 0 0
17 2 Roopavathy 48 2 - - 74 0 120 80 0 94 0 130 0 56 0 0 0
18 2 Pandian 47 1 - - 88 0 160 96 1 88 0 158 1 52 0 2 2
19 2 Shanthalaxmi 30 2 - - 78 0 120 80 0 82 0 122 0 52 0 0 0
20 2 Rajendran 44 1 - - 102 1 150 100 1 96 0 178 1 38 1 4 4
21 2 Mariammal 32 2 - - 78 0 120 80 0 108 1 132 0 56 0 1 1
22 2 Ramu 30 1 - - 86 0 120 80 0 146 1 144 0 58 0 1 1
23 2 Murugan 46 1 - - 88 0 120 80 0 86 0 132 0 48 0 0 0
24 2 Nagaraj 25 1 - - 84 0 120 80 0 89 0 122 0 52 0 0 0
25 2 Shanthi 36 2 - - 104 1 110 70 0 98 0 134 0 58 0 1 1
26 2 Govindasamy 46 1 - - 96 1 140 98 1 96 0 146 0 42 0 2 2
27 2 Rajesh 22 1 - - 78 0 120 80 0 92 0 148 0 48 0 0 0
28 2 Rajamani 47 2 - - 101 1 150 90 1 78 0 156 1 52 0 3 3
29 2 Nagammal 26 2 - - 78 0 110 80 0 78 0 128 0 62 0 0 0
30 2 Ravi 52 1 - - 102 1 150 100 1 148 1 146 0 38 1 4 4
31 2 Vasanthakumari 36 2 - - 104 1 120 80 0 132 1 156 1 48 1 4 4
32 2 Varadaraj 24 1 - - 82 0 120 80 0 78 0 134 0 46 0 0 0
33 2 Arul 40 1 - - 101 1 150 90 1 134 1 146 0 48 0 3 3
34 2 Nandakumar 30 1 - - 88 0 120 80 0 88 0 133 0 44 0 0 0
35 2 Indradevi 30 2 - - 78 0 140 90 1 92 0 134 0 58 0 1 1
36 2 Chinna thai 60 2 - - 76 0 160 100 1 134 1 140 0 52 0 2 2
37 2 Poomadhu 48 2 - - 103 1 120 80 0 89 0 192 1 44 1 3 3
38 2 Murugesan 58 1 - - 88 0 120 80 0 88 0 132 0 43 0 0 0
CONTROLS WITHOUT NEPHROLITHIASIS
S.No Group NAME AGEc SEX STONE SIDE STONE SIZE WAIST WC_gp SBP DBP BP_gp FBS FBS_gp TGL TGL_gp HDL HDL_gp TOTAL MSC
39 2 Rajesh 32 1 - - 97 1 120 80 0 92 0 154 1 48 0 2 2
40 2 Jeyanthi 37 2 - - 94 1 120 80 0 122 1 154 1 54 0 3 3
41 2 Sheela 37 2 - - 79 0 120 80 0 98 0 146 0 52 0 0 0
42 2 Ekambaram 43 1 - - 88 0 160 90 1 202 1 146 0 46 0 2 2
43 2 Lilly 33 2 - - 77 0 120 80 0 86 0 138 0 38 0 0 0
44 2 Velmurugan 38 1 - - 87 0 120 80 0 90 0 140 0 46 0 0 0
45 2 Ponni 37 2 - - 76 0 120 80 0 88 0 130 0 56 0 0 0
46 2 Madhan 22 1 - - 88 0 110 80 0 78 0 128 0 52 0 0 0
47 2 Kanagaraj 55 1 - - 82 0 150 90 1 172 1 180 1 38 1 4 4
48 2 Rani 50 2 - - 78 0 140 90 1 92 0 168 1 54 0 2 2
49 2 Raji 27 1 - - 86 0 120 80 0 88 0 134 0 48 0 0 0
50 2 Puspha 22 2 - - 78 0 110 70 0 76 0 122 0 60 0 0 0
51 2 Laxmi 33 2 - - 78 0 120 80 0 89 0 128 0 54 0 0 0
52 2 Fernandes 26 1 - - 103 1 120 80 0 90 0 172 1 34 1 3 3
53 2 Faritha 25 2 - - 76 0 120 80 0 84 0 130 0 62 0 0 0
54 2 Yuvaraj 20 1 - - 82 0 110 70 0 80 0 128 0 56 0 0 0
55 2 Babu 53 1 - - 104 1 160 90 1 126 1 146 0 32 1 4 4
56 2 Latha 21 2 - - 72 0 110 80 0 86 0 126 0 58 0 0 0
57 2 Arul kumar 23 1 - - 85 0 120 70 0 90 0 162 1 38 1 2 2
58 2 Shabena 28 2 - - 109 1 150 90 1 142 1 146 0 54 0 3 3
59 2 Sumithra 21 2 - - 72 0 120 80 0 82 0 134 0 58 0 0 0
60 2 Senthil kumar 26 1 - - 86 0 120 80 0 94 0 168 1 39 1 2 2
61 2 Mohammed Azar 24 1 - - 80 0 120 80 0 80 0 134 0 44 0 0 0
62 2 Kala 30 2 - - 77 0 120 80 0 86 0 136 0 58 0 0 0
63 2 Marimuthu 34 1 - - 84 0 120 80 0 97 0 158 1 46 0 1 1
64 2 Menaga 24 2 - - 74 0 120 80 0 94 0 156 1 52 0 1 1
65 2 Anandan 37 1 - - 87 0 120 80 0 89 0 146 0 46 0 0 0
66 2 Laxmi 55 2 - - 74 0 120 90 0 204 1 192 1 38 1 3 3
67 2 Mani 38 1 - - 85 0 120 80 0 92 0 202 1 36 1 2 2
68 2 Vijaya rangan 39 1 - - 82 0 120 84 0 98 0 198 1 32 1 2 2
69 2 chandrika 35 2 - - 74 0 120 80 0 80 0 134 0 56 0 0 0
70 2 Ramu 51 1 - - 80 0 150 90 1 122 1 182 1 32 1 4 4
71 2 Malarkodi 27 2 - - 73 0 120 80 0 84 0 140 0 54 0 0 0
72 2 Vasantha 55 2 - - 71 0 120 80 0 132 1 167 1 46 1 3 3
73 2 Sabeer 23 1 - - 88 0 120 80 0 88 0 146 0 46 0 0 0
74 2 Ikram Hussain 27 1 - - 87 0 120 80 0 128 1 180 1 38 1 3 3
75 2 Selvi 35 2 - - 98 1 140 90 1 80 0 158 1 54 0 3 3
76 2 Balaji 31 1 - - 82 0 120 80 0 92 0 140 0 48 0 0 0
77 2 Sarasa 55 2 - - 74 0 120 80 0 86 0 143 0 44 1 1 1
78 2 Janaki 48 2 - - 102 1 150 90 1 190 1 142 0 54 0 3 3
S.No Group NAME AGEc SEX STONE SIDE STONE SIZE WAIST WC_gp SBP DBP BP_gp FBS FBS_gp TGL TGL_gp HDL HDL_gp TOTAL MSC
79 2 Natarajan 30 1 - - 86 0 120 80 0 78 0 140 0 52 0 0 0
80 2 Perumal 60 1 - - 83 0 120 80 0 94 0 138 0 48 0 0 0
81 2 Rani 51 2 - - 75 0 120 80 0 131 1 134 0 56 0 1 1
82 2 Dharmaraj 28 1 - - 105 1 120 80 0 92 0 184 1 36 1 3 3
83 2 Sharmila 53 2 - - 74 0 124 80 0 80 0 138 0 62 0 0 0
84 2 Vetri 21 1 - - 78 0 120 80 0 90 0 142 0 60 0 0 0
85 2 Raman 36 1 - - 88 0 140 90 1 86 0 186 1 32 1 3 3
86 2 Anjalai 26 2 - - 96 1 120 80 0 87 0 140 0 56 0 1 1
87 2 Arjunan 28 1 - - 86 0 124 80 0 90 0 130 0 46 0 0 0
88 2 Gowri 33 2 - - 75 0 120 80 0 86 0 128 0 58 0 0 0
89 2 Suresh 23 1 - - 87 0 124 80 0 88 0 158 1 46 0 1 1
90 2 Paranthaman 40 1 - - 106 1 140 90 1 89 0 139 0 36 1 3 3
91 2 Devika 45 2 - - 101 1 122 80 0 86 0 156 1 46 1 3 3
92 2 Nandini 21 2 - - 78 0 110 80 0 84 0 126 0 62 0 0 0
93 2 Prabakaran 22 1 - - 100 1 140 100 1 96 0 190 1 36 1 4 4
94 2 Minalla 40 2 - - 95 1 140 96 1 112 1 142 0 54 0 3 3
95 2 Devi 36 2 - - 98 1 120 80 0 82 0 134 0 64 0 1 1
96 2 Venkatesh 26 1 - - 84 0 120 80 0 84 0 138 0 34 1 1 1
97 2 Bhuvaneswari 48 2 - - 96 1 120 80 0 92 0 140 0 56 0 1 1
98 2 Jayachithra 31 2 - - 90 1 110 70 0 84 0 130 0 62 0 1 1
99 2 Prabhu 27 1 - - 86 0 120 80 0 78 0 142 0 38 1 1 1
100 2 Akilandeswari 37 2 - - 96 1 120 80 0 92 0 138 0 58 0 1 1
Group-1: Individuals with Nephrolithiasis, Group-2: Individuals without Nephrolithiasis, WC- Waist Circumference, SBP- Systolic Blood Pressure
DPB- Diastolic Blood Pressure, FBS- Fasting Blood Sugar, TGL- Triglycerides, HDL- High Density Lipoprotein, MSC- Metabolic Syndrome Components
S.No Group NAME AGEc SEX STONE SIDE STONE SIZE WAIST WC_gp SBP DBP BP_gp FBS FBS_gp TGL TGL_gp HDL HDL_gp TOTAL MSC
1 1 Vanitha 25 2 LEFT 1.8 76 0 120 80 0 86 0 138 0 58 0 0 0
2 1 Arjunan 31 1 RIGHT 2.2 102 1 150 90 1 89 0 168 1 36 1 4 4
3 1 Kishore kumar 22 1 LEFT 1.6 88 0 120 80 0 80 0 142 0 42 0 0 0
4 1 Ramu 35 1 RIGHT 2 86 0 150 100 1 84 0 146 0 36 1 2 2
5 1 Manikandan 25 1 LEFT 1.5 105 1 120 80 0 90 0 132 0 42 0 1 1
6 1 Sussela 45 2 RIGHT 1.8 102 1 160 100 1 124 1 156 1 48 1 5 5
7 1 Srinivasan 35 1 RIGHT 2 87 0 120 80 0 230 1 142 0 56 0 1 1
8 1 Siddique 38 1 RIGHT 1.5 102 1 150 100 1 132 1 156 1 48 0 4 4
9 1 Basheer 45 1 RIGHT 2 82 0 124 80 0 86 0 134 0 48 0 0 0
10 1 Nithiyanantham 46 1 LEFT 1.8 106 1 140 90 1 82 0 134 0 46 0 2 2
11 1 Laxmi 30 2 LEFT 1.5 74 0 120 80 0 92 0 130 0 58 0 0 0
12 1 Pitchai 40 1 LEFT 1.7 98 1 140 90 1 138 1 137 0 38 1 4 4
13 1 Devaki 32 2 RIGHT 2.1 94 1 140 90 1 94 0 142 0 44 1 3 3
14 1 Banumathi 35 2 RIGHT 2.8 78 0 120 80 0 89 0 132 0 56 0 0 0
15 1 Subramani 42 1 RIGHT 1.9 85 0 140 100 1 204 1 168 1 32 1 4 4
16 1 Sathya 26 2 RIGHT 1.1 72 0 120 80 0 86 0 128 0 54 0 0 0
17 1 Maniyan 39 1 RIGHT 1.2 89 0 120 80 0 89 0 142 0 48 0 0 0
18 1 Dakchinamoorthy 53 1 LEFT 2.5 88 0 140 90 1 108 1 172 1 36 1 4 4
19 1 Jeganathan 31 1 LEFT 1.8 97 1 120 80 0 86 0 142 0 34 1 2 2
20 1 Rajalaxmi 35 2 LEFT 1 96 1 140 90 1 110 1 142 0 52 0 3 3
21 1 Lakshmi 47 2 RIGHT 1.9 90 1 150 100 1 126 1 162 1 43 1 5 5
22 1 Manoj 30 1 RIGHT 1 86 0 124 80 0 86 0 156 1 38 1 2 2
23 1 Subramani 42 1 RIGHT 1.5 85 0 120 80 0 78 0 142 0 54 0 0 0
24 1 Sasikala 24 2 LEFT 1.9 78 0 140 100 1 86 0 154 1 46 1 3 3
25 1 Laxmanan 32 1 LEFT 1.4 86 0 120 80 0 92 0 130 0 48 0 0 0
26 1 Vijaya 43 2 LEFT 1.1 106 1 160 100 1 129 1 180 1 52 0 4 4
27 1 Jayachandran 25 1 LEFT 1 88 0 120 80 0 80 0 140 0 50 0 0 0
28 1 Banu 43 2 RIGHT 1.1 92 1 140 90 1 98 0 172 1 46 1 4 4
29 1 Dakchinamoorthy 55 1 LEFT 1.3 86 0 160 100 1 86 0 142 0 48 0 1 1
30 1 Senthil nathan 45 1 RIGHT 0.8 99 1 120 80 0 142 1 174 1 42 0 3 3
31 1 Venkata Ramani 27 2 RIGHT 1.4 96 1 120 80 0 90 0 132 0 62 0 1 1
32 1 Bhavani 45 2 LEFT 1.8 92 1 150 100 1 122 1 157 1 52 0 4 4
33 1 Muthu 36 1 RIGHT 3 94 1 140 90 1 80 0 172 1 38 1 4 4
34 1 Chithra 33 2 LEFT 1.3 97 1 120 80 0 96 0 142 0 56 0 1 1
35 1 Inbasakaran 20 1 RIGHT 1.3 86 0 120 80 0 78 0 132 0 46 0 0 0
36 1 Kumar 35 1 RIGHT 1.6 103 1 150 100 1 114 1 164 1 44 0 4 4
37 1 Balasundari 28 2 RIGHT 1.3 102 1 140 90 1 120 1 132 0 52 0 3 3
38 1 Venkatesan 23 1 LEFT 1.4 78 0 120 80 0 88 0 164 1 38 1 2 2
CASES GROUP WITH NEPHROLITHIASIS
APPENDIX-IV
 MASTER CHART
S.No Group NAME AGEc SEX STONE SIDE STONE SIZE WAIST WC_gp SBP DBP BP_gp FBS FBS_gp TGL TGL_gp HDL HDL_gp TOTAL MSC
39 1 Balasubramaniyam 29 1 LEFT 1.2 104 1 140 90 1 128 1 168 1 48 0 4 4
40 1 Gnanasekari 25 2 RIGHT 1.3 76 0 120 80 0 90 0 130 0 56 0 0 0
41 1 Gandhimathi 46 2 RIGHT 1.5 98 1 160 100 1 134 1 159 1 54 0 4 4
42 1 Ramlingam 24 1 RIGHT 1.2 82 0 120 80 0 80 0 141 0 46 0 0 0
43 1 Baskar 38 1 RIGHT 1.6 107 1 140 90 1 94 0 162 1 39 1 4 4
44 1 Jessy Jane 38 2 LEFT 1.1 88 1 140 90 1 129 1 138 0 56 0 3 3
45 1 Arumugam 48 1 RIGHT 1.7 97 1 140 100 1 132 1 192 1 30 1 5 5
46 1 Kannagi 40 2 LEFT 0.8 98 1 140 100 1 128 1 146 0 51 0 3 3
47 1 Munusamy 24 1 LEFT 1 86 0 140 90 1 86 0 188 1 42 0 2 2
48 1 Cornalius 30 1 LEFT 1.9 106 1 150 90 1 86 0 142 0 42 0 2 2
49 1 Raju 38 1 RIGHT 2.6 96 1 140 90 1 94 0 169 1 49 0 3 3
50 1 Saraswathy 55 2 RIGHT 1.1 96 1 120 80 0 78 0 132 0 60 0 1 1
51 1 Krishnamoorthy 32 1 RIGHT 2 88 0 140 90 1 80 0 162 1 46 0 2 2
52 1 Krishnamoorthi 49 1 LEFT 1.3 108 1 148 100 1 126 1 198 1 38 1 5 5
53 1 Somasundaram 34 1 RIGHT 1.8 88 0 120 80 0 86 0 128 0 54 0 0 0
54 1 Nagasundari 30 2 RIGHT 1 96 1 120 80 0 90 0 140 0 56 0 1 1
55 1 Ponni 35 2 RIGHT 3.2 78 0 110 70 0 78 0 120 0 58 0 0 0
56 1 Chinnammal 50 2 RIGHT 2 96 1 120 80 1 88 0 168 1 44 1 4 4
57 1 Rajendran 44 1 RIGHT 1.1 106 1 140 90 1 89 0 169 1 37 1 4 4
58 1 Sukumari 29 2 LEFT 2 79 0 110 80 0 74 0 122 0 60 0 0 0
59 1 Swaminathan 39 1 LEFT 1.4 86 0 140 100 1 80 0 128 0 52 0 1 1
60 1 Malar 52 2 RIGHT 3 97 1 150 100 1 142 1 142 0 56 0 3 3
61 1 Suresh 43 1 LEFT 1.4 86 0 120 80 0 80 0 131 0 48 0 0 0
62 1 Amira 45 2 RIGHT 2 102 1 120 80 0 164 1 169 1 52 0 3 3
63 1 Raja Mohammed 30 1 RIGHT 2.3 82 0 120 80 0 90 0 140 0 48 0 0 0
64 1 Asohan 60 1 LEFT 2.2 86 0 120 80 0 88 0 148 0 38 1 1 1
65 1 Maroof 30 1 RIGHT 2 88 0 120 80 0 86 0 138 0 46 0 0 0
66 1 Senthil kumar 30 1 LEFT 2.3 86 0 150 90 1 122 1 130 0 52 0 2 2
67 1 Kamatchi 45 2 LEFT 2.6 104 1 120 80 0 132 1 186 1 51 0 3 3
68 1 Kumari 32 2 LEFT 1.5 76 0 120 80 0 84 0 128 0 60 0 0 0
69 1 Raja Sulochana 40 2 RIGHT 1.3 88 1 150 100 1 89 0 168 1 56 0 3 3
70 1 Rajeswari 41 2 RIGHT 1.4 96 1 120 80 0 166 1 172 1 42 1 4 4
71 1 Sethu 43 1 RIGHT 1.3 82 0 150 100 1 128 1 146 0 49 0 2 2
72 1 Karthiga 26 2 RIGHT 1.3 78 0 110 70 0 84 0 138 0 58 0 0 0
73 1 Velu 29 1 LEFT 1.2 104 1 150 100 1 88 0 157 1 34 1 4 4
74 1 Raghavi 54 2 RIGHT 1.5 87 1 120 80 0 139 1 184 1 56 0 3 3
75 1 Loganathan 33 1 RIGHT 2.6 105 1 160 100 1 79 0 170 1 36 1 4 4
76 1 Pughalendhi 34 1 RIGHT 1.5 86 0 120 80 0 92 0 138 0 44 0 0 0
77 1 Vijayalakshmi 45 2 LEFT 1.6 93 1 150 96 1 162 1 136 0 56 0 3 3
78 1 Jeyamani 40 2 RIGHT 0.8 76 0 120 80 0 90 0 129 0 54 0 0 0
79 1 Mahendran 45 1 LEFT 1.8 84 0 140 90 1 136 1 132 0 48 0 2 2
80 1 Periyasamy 49 1 RIGHT 1.4 99 1 150 90 1 142 1 143 0 38 0 3 3
S.No Group NAME AGEc SEX STONE SIDE STONE SIZE WAIST WC_gp SBP DBP BP_gp FBS FBS_gp TGL TGL_gp HDL HDL_gp TOTAL MSC
81 1 Veerammal 60 2 LEFT 2.2 78 0 120 80 0 120 1 136 0 46 1 2 2
82 1 Karunanithi 56 1 LEFT 1.1 83 0 120 80 0 92 0 132 0 42 0 0 0
83 1 Srinivasa Rao 34 1 RIGHT 1.4 107 1 124 80 0 84 0 138 0 49 0 1 1
84 1 Kumari 48 2 RIGHT 1.4 97 1 120 80 0 152 1 142 0 46 1 3 3
85 1 Kumara Selvi 30 2 LEFT 1.6 76 0 120 80 0 84 0 128 0 62 0 0 0
86 1 Arul 33 1 LEFT 1.6 109 1 150 100 1 97 0 134 0 46 0 2 2
87 1 Maniammal 43 2 LEFT 1.1 74 0 120 80 0 84 0 132 0 42 1 1 1
88 1 Harivel 41 1 RIGHT 1.3 80 0 122 80 0 96 0 138 0 50 0 0 0
89 1 Shanmuga Sundari 57 2 LEFT 1.4 92 1 160 100 1 90 0 142 0 42 1 3 3
90 1 Sanju 25 2 LEFT 1.7 74 0 110 70 0 86 0 128 0 62 0 0 0
91 1 Krishnaveni 47 2 RIGHT 0.8 96 1 120 80 0 82 0 124 0 62 0 1 1
92 1 Subramani 51 1 RIGHT 1.5 107 1 150 90 1 98 0 169 1 36 1 4 4
93 1 Latha 40 2 LEFT 1.5 76 0 120 80 0 86 0 140 0 54 0 0 0
94 1 Shantha 42 2 RIGHT 1.3 74 0 120 80 0 154 1 132 0 56 0 1 1
95 1 Geetha 43 2 LEFT 1.3 78 0 120 80 0 94 0 138 0 54 0 0 0
96 1 Ravi 35 1 LEFT 1.2 103 1 120 80 0 86 0 158 1 38 1 3 3
97 1 Rajammal 58 2 LEFT 1.3 78 0 120 80 0 90 0 126 0 62 0 0 0
98 1 Malathi 52 2 LEFT 1 99 1 150 100 1 186 1 132 0 59 0 3 3
99 1 Sri Kandhan 27 1 RIGHT 1.2 97 1 140 100 1 88 0 134 0 46 0 2 2
100 1 Abirami 37 2 LEFT 0.8 96 1 120 80 0 86 0 128 0 52 0 1 1
